Early onset of action of amineptine.

Abstract:

:A priority in the treatment of depression is to obtain rapid improvement at an early stage. Since depressed patients, who are often convinced that nothing can be done for them, may well have difficulty in adhering to the therapeutic management plan, they can be both uncooperative and neglectful of treatment measures. The rapid correction of this often resigned apathy is an essential aspect of treatment. According to a variety of clinical criteria, amineptine often achieves rapid improvement, particularly on measures of psychomotor retardation. Initially, antidepressant medication is an essential measure in the relief of depressive symptoms, although subsequently, it may also become a complement to psychotherapeutic support. Amineptine has been shown to act directly on the dopaminergic pathway, unlike other antidepressants, which act on this system only via their effects on the serotonergic or noradrenergic systems.

authors

Freeman H

doi

10.1097/00004850-199707003-00005

subject

Has Abstract

pub_date

1997-07-01 00:00:00

pages

S29-33

eissn

0268-1315

issn

1473-5857

journal_volume

12 Suppl 3

pub_type

杂志文章,评审
  • The emergence of tics during escitalopram and sertraline treatment.

    abstract::The selective serotonin reuptake inhibitors (SSRIs) have well-established antidepressant activity and have also demonstrated efficacy in a number of anxiety disorders, including panic disorder. The SSRIs, escitalopram and sertraline, are well-tolerated and movement disorders are rarely associated with their use. We pr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200505000-00010

    authors: Altindag A,Yanik M,Asoglu M

    更新日期:2005-05-01 00:00:00

  • Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.

    abstract::We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/YIC.0000000000000177

    authors: Pae CU,Wang SM,Han C,Bahk WM,Lee SJ,Patkar AA,Masand PS,Serretti A,Emsley R

    更新日期:2017-09-01 00:00:00

  • An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

    abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0000000000000121

    authors: Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

    更新日期:2016-05-01 00:00:00

  • Which antidepressants have demonstrated superior efficacy? A review of the evidence.

    abstract::A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282eff7e0

    authors: Montgomery SA,Baldwin DS,Blier P,Fineberg NA,Kasper S,Lader M,Lam RW,Lépine JP,Möller HJ,Nutt DJ,Rouillon F,Schatzberg AF,Thase ME

    更新日期:2007-11-01 00:00:00

  • Patient-based and clinician-based support for the remission criteria in schizophrenia.

    abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000224791.06159.88

    authors: Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

    更新日期:2007-01-01 00:00:00

  • Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.

    abstract::The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200109000-00004

    authors: Schutz G,Berk M

    更新日期:2001-09-01 00:00:00

  • 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.

    abstract::On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytrypt...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000321

    authors: Yousefzadeh F,Sahebolzamani E,Sadri A,Mortezaei A,Aqamolaei A,Mortazavi SH,Shalbafan MR,Ghaffari S,Alikhani R,Mousavi SB,Naderi S,Shamabadi A,Jalilevand S,Akhondzadeh S

    更新日期:2020-09-01 00:00:00

  • Elective combined electroconvulsive and clozapine therapy.

    abstract::Clozapine therapy does not produce the rapid response that may be required in severely disturbed patients. The latter, not uncommonly, obstruct treatment by refusing to give blood for haematological monitoring or refusing to swallow tablets. Whereas electroconvulsive therapy (ECT) may be used for rapid behavioural con...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199903000-00002

    authors: James DV,Gray NS

    更新日期:1999-03-01 00:00:00

  • Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.

    abstract::Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity. So far, the most promising results, that we report here, have been obtained with clozapine. To a les...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.yic.0000063501.97247.38

    authors: Potvin S,Stip E,Roy JY

    更新日期:2003-05-01 00:00:00

  • Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.

    abstract::To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders. Outpatients fulfilling DSM-III-R criteria for major depression or dysthymia and for a co-occurring comorbid anxiety disorder (panic disorder, generalized anxiety disorder or obsess...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200301000-00003

    authors: Pini S,Amador XF,Dell'Osso L,Baldini Rossi N,Cassano P,Savino M,Cassano GB

    更新日期:2003-01-01 00:00:00

  • Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

    abstract::Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

    更新日期:1996-06-01 00:00:00

  • ADDH and methylphenidate responders: effects on behavior controlled by complex reinforcement schedules.

    abstract::One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH). While laboratory-based evidence indicates that MPH effects may be rate-dependent, little is known about changes evinced in operant behavior controlled by compl...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198810000-00006

    authors: DuPaul GJ,Rapport MD,Vyse SA

    更新日期:1988-10-01 00:00:00

  • Somnambulistic-like behaviour in patients attending a lithium clinic.

    abstract::The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Landry P,Warnes H,Nielsen T,Montplaisir J

    更新日期:1999-05-01 00:00:00

  • Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale.

    abstract::The aim was to evaluate the efficacy of venlafaxine extended release (ER) on characteristics of resilience, measured by the Connor-Davidson Resilience Scale, in patients with posttraumatic stress disorder (PTSD). Data were evaluated from a randomized, 6-month, international, multicenter study of adult outpatients with...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e32830c202d

    authors: Davidson J,Baldwin DS,Stein DJ,Pedersen R,Ahmed S,Musgnung J,Benattia I,Rothbaum BO

    更新日期:2008-09-01 00:00:00

  • Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome.

    abstract::Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Horiguchi J,Yamashita H,Mizuno S,Kuramoto Y,Kagaya A,Yamawaki S,Inami Y

    更新日期:1999-01-01 00:00:00

  • Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.

    abstract::Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. I...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/01.yic.0000122861.35081.16

    authors: van Os J,Bossie CA,Lasser RA

    更新日期:2004-07-01 00:00:00

  • Clinical utility of milnacipran in comparison with other antidepressants.

    abstract::The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200206001-00006

    authors: Bisserbe JC

    更新日期:2002-06-01 00:00:00

  • Comparison of performance of healthy volunteers given prazepam alone or combined with ethanol. Relation to drug plasma concentrations.

    abstract::The interaction between a single dose of 20 mg of prazepam and 0.5 g/kg body weight ethanol was investigated in 12 healthy male volunteers by nine objective performance tests, eight visual analogue self-rating scales and measurement of prazepam and ethanol plasma concentrations, using a double-blind three-way crossove...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199100640-00004

    authors: Girre C,Hirschhorn M,Bertaux L,Palombo S,Fournier PE

    更新日期:1991-01-01 00:00:00

  • Efficacy of risperidone in treating the hyperactive symptoms of delirium.

    abstract::Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists sc...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200405000-00008

    authors: Liu CY,Juang YY,Liang HY,Lin NC,Yeh EK

    更新日期:2004-05-01 00:00:00

  • Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

    abstract::Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0000000000000016

    authors: Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

    更新日期:2014-03-01 00:00:00

  • Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.

    abstract::This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000218

    authors: Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

    更新日期:2018-07-01 00:00:00

  • Benzodiazepine exposure in subjects with incident Alzheimer's disease and related syndromes in France: a longitudinal study 2011-2017.

    abstract::Benzodiazepines are commonly used for behavioral and psychiatric symptoms of dementia, despite their numerous adverse effects and the lack of evidence regarding their efficacy in this context. We studied longitudinal benzodiazepines exposure in incident cases of Alzheimer's disease and related syndromes (ADRS) in Fran...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000312

    authors: Poncet M,Gardette V,Couret A,Renoux A,Lapeyre-Mestre M,Gallini A

    更新日期:2020-09-01 00:00:00

  • Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics.

    abstract::Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-200609000-00007

    authors: Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

    更新日期:2006-09-01 00:00:00

  • Nefazodone-induced clitoral priapism.

    abstract::A case is presented of painful priapism of the clitoris lasting 3 days, with a strong temporal association with the administration of nefazodone hydrochloride. Priapism has been described as a rare side-effect of drugs with high alpha1-adrenergic blocking potential. However, the alpha1-adrenergic blocking potential of...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199907000-00009

    authors: Brodie-Meijer CC,Diemont WL,Buijs PJ

    更新日期:1999-07-01 00:00:00

  • Use of perospirone for obesity and diabetes mellitus in patients with schizophrenia: three case reports.

    abstract::We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200401000-00008

    authors: Nishida M,Nakamura M

    更新日期:2004-01-01 00:00:00

  • Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

    abstract::Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000097

    authors: Peselow ED,Clevenger S,IsHak WW

    更新日期:2016-07-01 00:00:00

  • Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

    abstract::The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.yic.0000137184.64610.c8

    authors: Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

    更新日期:2004-09-01 00:00:00

  • Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia.

    abstract::Although the effects of atypical antipsychotics with regard to improving neurocognitive function are not sufficiently high. The present study applied an atypical antipsychotic monotherapy for patients with acute schizophrenia to (1) examine the percentage of patients who respond well to this treatment, (2) explore the...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000293

    authors: Hori H,Yoshimura R,Katsuki A,Atake K

    更新日期:2020-03-01 00:00:00

  • Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.

    abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Eriksson E

    更新日期:1999-05-01 00:00:00

  • Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.

    abstract::The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200111000-00002

    authors: Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

    更新日期:2001-11-01 00:00:00